Genomics

Dataset Information

0

Identification of resistance mechanisms to anti-HER2 antibody in breast cancer cell line BT-474


ABSTRACT: Background: The addition of the anti-HER2 antibody pertuzumab to trastuzumab/chemotherapy treatment in HER2+ breast cancer significantly improves clinical outcome. Concomitantly, the drug-antibody conjugate T-DM1 (trastuzumab-emantasine) has demonstrated efficacy, at least equal, to the combination of trastuzumab/chemotherapy. Scientific, economic and health challenges emerge from the clinical use of these novel anti-HER2 antibodies, aimed to identify new resistance mechanisms and to select the target breast cancer population. Objectives: (1) To identify primary resistance mechanisms to anti-HER2 antibodies trastuzumab, pertuzumab, and to the combined trastuzumab/pertuzumab or pertuzumab/T-DM1 therapy, (2) To identify acquired resistance mechanisms to anti-HER2 antibodies trastuzumab, pertuzumab, and to the combined trastuzumab/pertuzumab or pertuzumab/T-DM1 therapy, (3) To develop new combinations of anti-HER2 antibodies with other targeted therapies. Overall design: Samples: Breast cancer cell line BT-474. Treatments: trastuzumab-conditioned cultures. Control samples: same cell lines with no treatment. Triplicates.

INSTRUMENT(S): [HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version]

ORGANISM(S): Homo sapiens  

SUBMITTER: Juan Madoz-Gúrpide  

PROVIDER: GSE89216 | GEO | 2019-12-31

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
GSE89216_RAW.tar Raw
filelist.txt Txt
Items per page:
1 - 2 of 2

Similar Datasets

2020-01-01 | S-EPMC7293079 | BioStudies
2014-01-01 | S-EPMC4260046 | BioStudies
2017-01-01 | S-EPMC5704598 | BioStudies
2017-01-01 | S-EPMC5455677 | BioStudies
2020-01-01 | S-EPMC7520337 | BioStudies
2013-01-01 | S-EPMC3563710 | BioStudies
2017-01-01 | S-EPMC5605415 | BioStudies
2019-01-01 | S-EPMC6784849 | BioStudies
2020-01-01 | S-EPMC7191090 | BioStudies
2020-01-01 | S-EPMC7812178 | BioStudies